Zobrazeno 81 - 90
of 1 548
pro vyhledávání: ''
Autor:
Max M. Quinn, Xiaoen Wang, Cyril H. Benes, Ashley A. Merlino, Qingsong Liu, Yuyang Li, Peng Gao, Kwok-Kin Wong, Nathanael S. Gray, Feiyang Liu, Fei Li, Yan Liu
Publikováno v:
Cancer Research. 77:5068-5076
Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/
Autor:
Levi Sokol, Kim M. Hirshfield, Chandrika Jeyamohan, Srilatha Simhadri, Janice M. Mehnert, Lorna Rodriguez-Rodriguez, Husam Al-Hraishawi, Shridar Ganesan, Sharon R. Pine, Atul Kulkarni, Suzie Chen, Man Lung Teo, Eileen White, Siraj M. Ali
Publikováno v:
Clinical Cancer Research. 23:5631-5638
Purpose: Many patients with BRAFV600E mutant melanoma treated with BRAF inhibitors experience a rapid response, but ultimately develop resistance. Insight into the mechanism of resistance is critical for development of more effective treatment strate
Autor:
Raghu Kalluri, Chanjuan Shi, Valerie M. Weaver, Anna Chytil, Harold L. Moses, Fei Ye, Philip Owens, Sergey V. Novitskiy, Michael W. Pickup, Agnieszka E. Gorska
Publikováno v:
Cancer immunology research, vol 5, iss 9
The survival rate for pancreatic ductal adenocarcinoma (PDAC) remains low. More therapeutic options to treat this disease are needed, for the current standard of care is ineffective. Using an animal model of aggressive PDAC (Kras/p48TGFβRIIKO), we d
Autor:
Byung-Gyu Kim, Hye Jin Ham, Jung-Guk Kim, Ji-Hyun Kim, Soo-Young Park, Keun-Gyu Park, Jung Yi Lee, Yeon-Kyung Choi, Se Young Jang, Mi Jin Kim, Hui-Jeon Jeon, Inkyu Lee
Publikováno v:
Molecular Cancer Research. 15:1230-1242
The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high. Here, we report metabolic reprogramming in sorafenib-resistant
Autor:
Chun Gong, Fei-jiao Ge, Ming Ni, Jianming Xu, Rongrui Liu, Chuanhua Zhao, Jun-Yan Gu, Yan Wang, Zhaoli Tan, Ru Jia, Mansheng Li, Shuji Ogino, He-Fei Wang, Yang Jin, Yunping Zhu, Li Lin, Youliang Wang, Yu Ling Chen, Tao Liu, Zhi Rong Qian
Publikováno v:
Clinical Cancer Research. 23:4602-4616
Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of
Autor:
Si-Yang Liu, Qing Zhou, Lan-Ying Gou, A. Li, Zhi-Hong Chen, Bin Gan, Hua-Jun Chen, Bin-Chao Wang, Jian Su, Chong-Rui Xu, Qi Zhang, Jin-Ji Yang, Zheng Wang, Xue-Ning Yang, Zhenfan Yang, Shannon Chuai, Han Han-Zhang, Zhen Wang, Zhi Xie, Wen-Zhao Zhong, Zhou Zhang, Yu Bai, Xu-Chao Zhang, Si-Pei Wu, Ben-Yuan Jiang, Hong-Fei Gao, Yi-Long Wu
Publikováno v:
Clinical Cancer Research. 23:4929-4937
Purpose: MET amplification, responsible for 20% of acquired resistance to EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non–small cell lung cancer (NSCLC), presents an attractive target. Numerous studies have conferred susceptibili
Publikováno v:
Molecular Cancer Therapeutics. 16:1658-1668
A subset of non–small cell lung cancers (NSCLC) are dependent upon oncogenic driver mutations, including the most frequently observed driver mutant KRAS, which is associated with a poor prognosis. As direct RAS targeting in the clinic has been unsu
Autor:
Petros Grivas
Publikováno v:
Clinical Cancer Research. 25:907-909
Cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy is standard in fit patients. Inactivating mutations of the nucleotide excision repair gene ERCC2 can predict response to cisplatin-based chemotherapy. Evaluation of the functional i
Autor:
Timothy P. Heffernan, Annette Machado, Ulrich Duenzinger, Joseph R. Marszalek, Christopher P. Vellano, Michael Gmachl, Mark Petronczki, Dorothea Rudolph, Daniel Gerlach, Marco H. Hofmann, Francesca Trapani, Vitomir Vucenovic, Norbert Kraut, Marcelo Marotti, Joseph R. Daniele, Irene Waizenegger, Hengyu Lu
Publikováno v:
Cancer Research. 81:CT210-CT210
The SOS1i::KRAS inhibitor BI 1701963 is the first direct RAS signaling modifier to enter phase I clinical trials both as a monotherapy as well as in combination. SOS1::KRAS inhibitors exhibit activity against a broad spectrum of KRAS alleles, includi
Autor:
Kazuo Kasahara, Takashi Sone, Satoshi Watanabe, Hiroki Matsuoka, Mohiuddin, Nanao Terada, Keigo Saeki, Hideharu Kimura, Miki Abo
Publikováno v:
Cancer Research. 81:LB099-LB099
Background: Pemetrexed disodium heptahydrate (pemetrexed) is currently used for the treatment of patients with advanced non-small cell lung cancer (NSCLC). More than 30% of lung cancer cases involve KRAS mutations. In this study, we examined the anti